erlotinib hydrochloride has been researched along with pf-06463922 in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (pf-06463922) | Trials (pf-06463922) | Recent Studies (post-2010) (pf-06463922) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 229 | 27 | 224 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | pf-06463922 (IC50) |
|---|---|---|---|
| Sodium-dependent phosphate transport protein 2B | Homo sapiens (human) | 0.0002 | |
| HLA class II histocompatibility antigen gamma chain | Homo sapiens (human) | 0.0002 | |
| High affinity nerve growth factor receptor | Homo sapiens (human) | 0.024 | |
| Tyrosine-protein kinase Fes/Fps | Homo sapiens (human) | 0.006 | |
| Proto-oncogene tyrosine-protein kinase ROS | Homo sapiens (human) | 0.0003 | |
| Tyrosine-protein kinase Fer | Homo sapiens (human) | 0.0033 | |
| Leukocyte tyrosine kinase receptor | Homo sapiens (human) | 0.0027 | |
| Tyrosine-protein kinase FRK | Homo sapiens (human) | 0.053 | |
| Focal adhesion kinase 1 | Homo sapiens (human) | 0.017 | |
| Activated CDC42 kinase 1 | Homo sapiens (human) | 0.017 | |
| Protein-tyrosine kinase 2-beta | Homo sapiens (human) | 0.014 | |
| NT-3 growth factor receptor | Homo sapiens (human) | 0.046 | |
| Echinoderm microtubule-associated protein-like 4 | Homo sapiens (human) | 0.0186 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.0177 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benes, CH; Damon, LJ; Dardaei, L; Dastur, A; Dicecca, R; Engelman, JA; Farago, AF; Fintelmann, FJ; Friboulet, L; Gainor, JF; Greenberg, M; Held, MA; Kattermann, KE; Kodack, DP; Lee, D; Niederst, MJ; Parks, M; Piotrowska, Z; Riley, AK; Rizzo, C; Sequist, LV; Shaw, AT; von Flotow, F | 1 |
| Higo, H; Hotta, K; Ichihara, E; Kano, H; Kayatani, H; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Matsubara, T; Ninomiya, K; Ninomiya, T; Nishii, K; Ohashi, K; Rai, K; Sato, A; Tabata, M; Takata, M; Tomida, S; Toyooka, S; Watanabe, H | 1 |
2 other study(ies) available for erlotinib hydrochloride and pf-06463922
| Article | Year |
|---|---|
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
Topics: Acrylamides; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Feeder Cells; Fluorescent Antibody Technique; Gene Expression; High-Throughput Screening Assays; Humans; Keratin-18; Keratin-8; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neoplasms; Piperazines; Precision Medicine; Primary Cell Culture; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2017 |
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lactams; Lactams, Macrocyclic; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Middle Aged; Mutation; Piperidines; Pyrazoles; Xenograft Model Antitumor Assays | 2019 |